Contingencies and commitments
Contractual obligations and commitments
We have certain purchase commitments principally with CRO subcontractors and certain collaboration partners.
On 31 March 2020, we had outstanding obligations for purchase commitments, which become due as follows:
(thousands of €) |
Total |
Less than |
1 - 3 years |
3 - 5 years |
More than |
Purchase commitments |
266,330 |
192,869 |
66,291 |
6,912 |
258 |
In addition we have engaged a property developer for the construction of a building in Leiden.
At 31 March 2020, we were committed to leases which have not yet started. The total future cash outflows for leases that had not yet commenced were as follows:
(thousands of €) |
Total |
Less than |
1 - 3 years |
3 - 5 years |
More than |
Lease commitments not commenced |
8,986 |
5,793 |
1,502 |
1,502 |
188 |
In addition to the table above, we have a contractual cost sharing obligation related to our collaboration agreement with Gilead for filgotinib. The contractual cost sharing commitment amounted to €602.8 million at 31 March 2020 for which we have direct purchase commitments of €25.8 million at 31 March 2020 reflected in the table above.
Contingent liabilities and assets
We refer to our Annual Report 2019 for a description of our contingent liabilities and assets.